Hematologic Cancers

Triplet Maintenance After HSCT Improves PFS vs Lenalidomide Alone in Multiple Myeloma

By

Jonathan Goodman, MPhil

Publish Date June 24, 2022

Results of the phase 3 ATLAS trial revealed a potential new standard of care, according to researchers.

Predicting Disease Progression in Patients With MALT Lymphoma

By

John Schieszer

Publish Date June 24, 2022

The researchers examined the prognostic significance of AMC and LMR in 316 patients with MALT lymphoma.

Rusfertide for Patients With Phlebotomy-Dependent Polycythemia Vera

By

Vicki Moore, PhD

Publish Date June 23, 2022

Rusfertide demonstrated activity in reducing hematocrit levels in patients with polycythemia vera in two phase 2 clinical trials.

Features of Fever of Unknown Origin Later Diagnosed as Lymphoma

By

Vicki Moore, PhD

Publish Date June 23, 2022

Researchers sought to define clinical and prognostic features associated with fever of unknown origin in patients later diagnosed with lymphoma.

Venetoclax Plus Obinutuzumab May Improve PFS, Not OS in Chronic Lymphocytic Leukemia

By

Jonathan Goodman, MPhil

Publish Date June 16, 2022

Patients with previously untreated CLL had superior PFS with fixed duration venetoclax plus obinutuzumab, with or without ibrutinib.